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Abstract
All 13C NMR studies of brain glycogen to date relied on observing the incorporation of 13C label into glycogen, and thus interpretation was
potentially affected by changes in 13C label turnover rates. The goal of this study was to quantify total brain glycogen concentration under
conditions of hypoglycemia or normoglycemia using biochemical methods. Rats were sacrificed using a focused microwave fixation device. The
results showed that metabolism of brain glycogen was Glc- and insulin-sensitive and that insulin-induced hypoglycemia promoted a gradual
glycogenolysis. Moreover, we show that there are very mild effects of isoflurane and a-chloralose anesthesia on brain glycogen concentration.
Altogether these results show that total brain glycogen serves as a substantial source of glucosyl units during insulin-induced moderate
hypoglycemia and therefore may be neuroprotective. Finally we also conclude that previous interpretation of 13C NMR spectroscopy data
accurately reflected the changes in total brain glycogen content.
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Glucose (Glc) is the main substrate for brain energy
metabolism. Although the brain relies on a continuous supply
of Glc for normal function, it has been proposed based on
studies using 13C NMR spectroscopy in conjunction with
infusion of 13C labeled glucose (Choi et al., 2000; Choi et al.,
1999), that brain glycogen can serve as a substantial source of
Glc equivalents during acute insulin-induced hypoglycemia
(Choi et al., 2003; Gruetter, 2003). Brain glycogen is known to
exert a neuroprotective effect (Brown et al., 2003). However,
the ability of brain glycogen to provide Glc equivalent to brain
energy metabolism has been questioned: Whereas it has been
stated that brain cannot store more than a few minutes’ supplyAbbreviations: ATP, adenosine tri-phosphate; Glc, glucose; I.U., insulin
unit; I.V., intravenous; NMR, nuclear magnetic resonance
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doi:10.1016/j.neuint.2005.12.034as glycogen (reviewed in Cryer et al., 2003), we suggested that
glycogen stores are not completely depleted after 2 h of
hypoglycemia (Choi et al., 2003). Recent studies using 13C
NMR spectroscopy have shown that brain glycogen metabo-
lism was very slow both in light a-chloralose anesthetized rats
(Choi et al., 1999) and in human subjects (Oz et al., 2003), and
that the total concentration of brain glycogen in the awake,
normoglycemic rat was 3.3  0.8 mmol/g (Choi and Gruetter,
2003). All NMR studies of brain glycogen to date were
performed in conjunction with observing the incorporation of
13C label into brain glycogen. The interpretation of 13C NMR
data was potentially complicated by the fact that only the
labeled part of the molecule is measured and therefore
potentially suffers from the limitation related to 13C label
turnover. On the other hand, using biochemical methods
following brain extraction to measure metabolically labile
compounds such as glycogen needs to address post-mortem
artifacts (Swanson and Choi, 1993). It is difficult to
quantitatively account for all of the possible metabolic products
that might be quickly generated due to rapid post-mortem
degradation (Cruz and Dienel, 2002).
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most numerous cells in the brain, which are distributed
throughout the brain (Savchenko et al., 2000; Sloane et al.,
2000). In culture, it has been shown that both hyperglycemia
(Swanson et al., 1989) and insulin increased glycogen content
(Dringen and Hamprecht, 1992). In vivo, the concentration of
brain glycogen can be influenced by glucose (Goldberg and
O’Toole, 1969; Nelson et al., 1968) and insulin seems to
promote glycogenesis as well in the brain (Choi et al., 2003;
Daniel et al., 1977; Strang and Bachelard, 1971). These early
studies were performed in the presence of rather high
concentrations of plasma glucose. Therefore, it was not clear
whether these effects of insulin on glycogen content were only
achieved in supraphysiologic hyperglycemic conditions
(Daniel et al., 1977) or if brain glycogen might be regulated
by both insulin-dependent and insulin-independent mechan-
isms. Therefore, determining the relative contribution of each
may have great relevance to type-1 diabetes (reviewed in
Brown, 2004; Gruetter, 2003).
Concentrations of brain glycogen can be further influenced
by neurotransmitters (Magistretti et al., 1986; Pellerin and
Magistretti, 1994) and anesthetics (Nelson et al., 1968;
Nordstrom and Siesjo, 1978). Apparently, the degree of brain
glycogen increase seems to be related to the depth, duration,Table 1
Description of the experimental groups studied
Groups
of rats
‘‘Identifiers’’ n Prior anesthesia Tim
A Fasted only 6 Overnight fasted 1
B 48 h 10% Glc 7 Overnight fasted and
then fed ad lib. for 48 h
with 10% Glc sol. only
1
C Preparation only 4 Overnight fasted Ra
D 1 h 45 min under
isoflurane
4 Overnight fasted and
then fed ad lib. for 48 h
with 10% Glc sol. only
1 h
No
E 8 h a-chloralose 5 Overnight fasted Ra
F 5 h a-chloralose 5 Overnight fasted Ra
G Insulin (6 I.U./kg/h)
and 5 mM plasma Glc
5 Overnight fasted Ra
H Insulin (6 I.U./kg/h)
and 10 mM plasma Glc
5 Overnight fasted Ra
I Somatostatin (0.75 mg/kg/min)
and 10 mM plasma Glc
5 Overnight fasted Ra
J Somatostatin (0.75 mg/kg/min)
and 20 mM plasma Glc
5 Overnight fasted Ra
K Short acute hypoglycemia 5 Overnight fasted Ra
L Long acute hypoglycemia 6 Overnight fasted Ra
Data are shown as average  S.E.M. ad lib., ad libitum; Glc, glucose; n, numberand type of anesthesia used, with pentobarbital producing
greater increases in glycogen content than, for example, ether
(Nelson et al., 1968).
The goal of this study was to measure total brain glycogen
concentration during different glycemic states, including
hypoglycemia, using microwave fixation and biochemical
methods (Cruz and Dienel, 2002) in rats under light anesthesia.
2. Methods
2.1. Groups of animals studied
Table 1 summarizes the 12 different experimental groups. In groups A, B
and D, blood was collected by tail bleed. The two groups of rats that underwent
hypoglycemia (groups K and L) were treated as previously described (Choi
et al., 2001). Hypoglycemia was achieved by infusing 12 insulin Units/h/kg and
adjusting plasma Glc levels between 1 and 2 mmol/l.
2.2. Animal preparation
The study was performed according to the guidelines for the care and use of
laboratory animals at the University of Minnesota and was approved by the
Institutional Animal Care and Use Committee (IACUC).
Male Sprague–Dawley rats (271  4 g, Harlan, Madison, WI, USA) were
fasted overnight with free access to water before studies. They were anesthe-
tized using isoflurane (isoflurane, Halocarbon Laboratories, 5% for inductione under isoflurane anesthesia Time under a-chloralose anesthesia
0 min isoflurane only. No preparation –
0 min isoflurane only. No preparation –
t preparation (1 h 47 min  5 min) –
45 min  13 min under isoflurane.
preparation
–
t preparation (1 h 42 min  8 min) I.V. infusion of a-chloralose
ONLY (8 h 8 min  3 min)
t preparation (1 h 36 min  4 min) I.V. infusion of a-chloralose
ONLY (5 h  1 min)
t preparation (1 h 25 min  13 min) 5 h 4 min  5 min
t preparation (1 h 53 min  4 min) 4 h 38 min  8 min
t preparation (1 h 52 min  5 min) 4 h 59 min  6 min
t preparation (1 h 50 min  7 min) 4 h 54 min  5 min
t preparation (1 h 47 min  4 min) I.V. inf. of Glc (plasma
Glc: 13.9  0.7 mM) during
3 h followed by 30 min
hypoglycemia. Time
under a-chloralose anesthesia:
5 h 1 min  3 min
t preparation (1 h 58 min  17 min) I.V. inf. of Glc (plasma
Glc: 13.7  0.7 mM during
3 h followed by 2 h hypoglycemia.
Time under a-chloralose
anesthesia: 5 h 54 min  28 min
of rats; inf., infusion; I.U., insulin unit; I.V., intravenous; sol., solution.
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oxygen (O2) gases for preparation. Then, rats were intubated and ventilated
with a pressure-driven ventilator (Kent Scientific, Litchfield, CT, USA) during
the rest of the experiment (Table 1: groups C and E–L). End tidal CO2,
respiratory rate and pattern were monitored during rat preparation and
experiments with a capnometer (SurgiVet, Waukesha, WI, USA). Preparation
consisted of inserting catheters into both femoral arteries for blood gases and
Glc analysis, and into both femoral veins for intravenous (I.V.) infusion of a-
chloralose (Sigma), Glc (Mallinckrodt), insulin (Humulin R, Eli Lilly and
Company, Indianapolis, IN, USA) and somatostatin (octreotide acetate [San-
dostatin], Novartis).
2.3. Animal anesthesia
Immediately after rat preparation, anesthesia was switched to a-chloralose,
which was administered I.V. as follows: 30 min after a 40 mg/kg bolus injection,
a continuous I.V. infusion was started (26.7 mg/kg/h) to maintain a light
anesthesia state according to previous report (Ueki et al., 1992). All solutions
used for I.V. infusion were diluted in Dulbecco’s phosphate-buffered saline
(dPBS without calcium chloride and without magnesium chloride, BioWhit-
taker, Maryland, USA).
Rat body temperature was maintained at 37.0  0.5 8C with a heating plate
system (LAB-line slide warmer) based on a feedback obtained from a rectal
temperature probe (Cole Palmer, Vernon Hills, IL, USA).
Arterial blood was withdrawn from the femoral artery through a poly-
ethylene tubing line (PE50, Becton Dickinson) at least every 30 min. About
0.05 ml of blood was kept to measure physiological parameters with a pH/blood
gas analyzer (model 248, RapidLab, BAYER) and the rest of the blood
(0.15 ml) was immediately centrifuged after sampling to obtain plasma.
Plasma Glc concentration was measured using the glucose oxidase method
in a Glc analyzer (GM7 Micro-stat, Analox instruments, London, UK). Phy-
siologic parameters (respiration rate, breathing volume and cut-off) were
adjusted throughout the experiments to maintain pCO2 and pH within normal
physiological ranges (Table 2).
The infusion rate of Glc (20% w/v in dPBS) was continuously adjusted
based on the measured plasma Glc concentrations to maintain target plasma
glycemic levels.
2.4. Animal sacrifice and brain extraction
At the end of each experiment, rats were sacrificed using a focused
microwave fixation device (by applying 4 kW onto a 2 ml volume for 1.4 s)
(Gerling Applied Engineering Inc.) which inactivates most brain enzymes
before extraction or digestion, thereby minimizing possible in vitro glycogen
loss (Kong et al., 2002). The anterior parts of the brain (i.e. excluding
cerebellum) were dissected, and immediately placed into liquid nitrogen and
manually reduced to powder with a mortar and a pestle. Brain powder was
stored for less than 6 weeks at 80 8C.Table 2
Physiologic parameters
‘‘Identifiers’’ n Plasma Glc (mmol/l) pH
All groups during rat
preparation (i.e. C, E, F,
G, H, I, J, K, and L)
36 10.6  0.3 7.49 
E 5 7.1  0.1 7.41 
F 5 7.5  0.4 7.41 
G 5 4.9  0.1 7.41 
H 5 10.2  0.5 7.35 
I 5 10.4  0.1 7.40 
J 5 20.8  0.2 7.38 
K 4 1.7  0.1 7.31 
L 6 1.7  0.0 7.34 
Data are shown as mean  S.E.M. Values are averaged during the last hours of experi
do not include the values obtained during rat preparation (except for the first line)2.5. Glycogen assay
Biochemical measurement of brain glycogen was performed on the brain
extracts as previously described (Cruz and Dienel, 2002). Briefly, 0.03N HCl
(500 ml) was carefully added to frozen brain powders (200 mg) in tubes on dry
ice. Brain powders were homogenized (ultrasonic processor, Cole-Parmer
Instruments, Vernon Hills, Illinois, USA), heated to 90 8C for 45 min and
homogenized again.
For the glycogen assay, sodium acetate (Sigma) was added to 200 ml of ice-
cold samples in 0.03N HCl to attain a final concentration of 0.1 mM sodium
acetate. Well-mixed portions of each sample were incubated at 37 8C for at least
2 h with gentle mixing (reciprocal water bath shaker, model R76, New Bruns-
wick Scientific, Edison, NJ, USA) in two parallel aliquots, one containing
amylo-a-1,4-a-1,6-glucosidase (24 mg/ml, Roche) to convert glycogen to Glc
and the other without amylo-a-1,4-a-1,6-glucosidase. The samples were
centrifuged subsequently to remove particulate matter, and Glc levels were
determined in measured aliquots of the supernatant fraction using the same
Analox instrument as above. Glycogen levels per gram wet weight were
calculated as Glc released by amylo-a-1,4-a-1,6-glucosidase, that is, Glc level
after incubation with amyloglucosidase minus that without the enzyme (Ghajar
et al., 1982).
2.6. Lactate assay
To evaluate potential post-mortem glycogenolysis and glucose breakdown,
tissue lactate levels were assessed in parallel in the supernatant fraction. These
measurements were performed using a highly specific method measuring
oxygen consumption necessary for the oxidation of L-lactate into pyruvate
by an oxygen reductase (GMRD-090 lactate reagent kit, Analox Instruments,
USA) on the Analox reader (same as above). Measurements were excluded
when brain lactate concentration exceeded 3.0 mmol/g.
2.7. Statistical analysis
The statistical analysis was performed using the SAS package (SAS
Institute Inc., Cary, NC). Brain glycogen concentrations of different groups
of rats were compared using the analysis of variance, followed by the Tukey test
for multiple comparisons between means (GLM procedure). The linear regres-
sion model was used to check the correlation between brain glycogen and brain
glucose measurements (considered as covariable) and to compare the slope and
intercepts of the regression lines in different groups.
3. Results
First, we compared brain glycogen concentrations obtained
under different levels and types of anesthesia. Comparing brain
glycogen concentrations between the groups of rats that werePCO2 (mmHg) PO2 (mmHg) Body temp. (8C)
0.01 32.1  0.8 149.0  6.3 37.0  0.1
0.01 37.1  0.1 146.2  6.8 37.1  0.1
0.01 35.1  1.8 152.1  12.4 37.1  0.0
0.01 38.0  0.7 145.1  5.8 37.1  0.0
0.01 42.4  0.9 135.6  5.2 37.2  0.0
0.01 39.9  1.0 130.0  5.9 37.1  0.0
0.00 41.7  0.9 146.0  8.2 37.2  0.1
0.01 41.5  1.3 159.7  11.5 37.0  0.2
0.02 37.9  1.6 191.0  32.0 37.0  0.2
ments (e.g. during insulin or somatostatin infusion, etc.). Therefore, these values
. Glc, glucose; temp., temperature.
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Fig. 2. Comparison of brain Glc, as a function of plasma Glc, under isoflurane
(2%) and a-chloralose anesthesia (26.7 mg/kg/h). The concentration of brain
glucose measured by biochemical assay in post-mortem rat brain samples is
plotted as a function of plasma glucose concentration. The solid line, which
represents the best fit of the reversible Michaelis–Menten model of glucose
transport described previously (Choi et al., 2001; Gruetter et al., 1998), is in
agreement with the biochemical measurements presented here. Abbreviation:
Glc, glucose.
Fig. 1. Effects of anesthetics on brain glycogen concentration. Approximately
1 h 45 min under isoflurane anesthesia result in an increase in brain glycogen
(compare group C with groups A and B). However, eight additional hours under
a-chloralose anesthesia do not significantly increase brain glycogen concen-
tration further (compare E with C). Overnight fasting (compare group Awith B)
did not substantially affect brain glycogen. Error bars indicate S.E.M. Sig-
nificant differences between groups (with Tukey test, P < 0.05) are indicated by
*. Abbreviation: Glc, glucose.shortly induced with isoflurane (Table 1 and Fig. 1: groups A
and B) with the rats that underwent 1 h 45 min anesthesia
under isoflurane (Table 1 and Fig. 1: group C) before being
sacrificed indicated that 1 h 45 min of isoflurane anesthesia
caused a small increase in brain glycogen concentration of
0.6 mmol/g/h (Fig. 1: compare group A or B with C). Eight
additional hours of a-chloralose anesthesia produced no
discernable change in brain glycogen concentration (Fig. 1:
compare group C with E), although after 5 h of a-chloralose
anesthesia (Table 1: group F, average brain glycogen  S.E.M.:
5.8  0.2 mmol/g) brain glycogen was slightly higher than the
concentration observed in rats that only underwent a
preparation under isoflurane anesthesia (Table 1: group C,
average brain glycogen  S.E.M.: 4.6  0.2 mmol/g) (two-
tailed t-test assuming equal variance, P < 0.01, not shown).
Taken together these results show that there were very mild
effects of isoflurane and light a-chloralose anesthesia (26.7 mg/
kg/h I.V.) on brain glycogen concentration.
Second, we studied whether overnight fasting affected brain
glycogen. Comparing the rats which were fasted the night prior
sacrifice (Table 1 and Fig. 1: group A) with the rats which were
fasted two nights before and then fed for 48 h with a 10% Glc
solution (Table 1 and Fig. 1: group B) showed that neither
overnight fasting nor the 48 h Glc feeding regime substantially
affected brain glycogen content. Moreover, the preparation
itself neither affected brain glycogen concentration as judged
from comparison of groups C with D (average brain
glycogen  S.E.M.: group C: 4.6  0.2 mmol/g and group D:
4.8  0.1 mmol/g). Finally, the biochemical measurements of
brain glycogen in the two groups of rats that were fed with Glc
10% for 48 h (averaged brain glycogen concentra-
tion  S.E.M.: 3.6  0.2 mmol/g in group B with short
isoflurane anesthesia and 4.8  0.1 mmol/g in group D after
1 h 45 min under isoflurane anesthesia) were in excellent
agreement with previous 13C NMRmeasurements of total brainglycogen which reported a brain glycogen concentra-
tion  S.E.M. of 3.3  0.3 mmol/g (Choi and Gruetter, 2003).
Then, we assessed the transport kinetics of cerebral glucose
by plotting biochemical post-mortem measurements of brain
glucose concentration as a function of plasma glucose
concentrations measured just prior to sacrifice (Fig. 2). As
previously reported in a-chloralose lightly anesthetized rats,
the brain Glc concentration was a linear function of the plasma
Glc concentration (Choi et al., 2001; Choi et al., 2002). There
was no significant difference in the distribution of brain Glc
concentration in the isoflurane anesthetized rats (Fig. 2: open
squares) compared to a-chloralose anesthetized rats (Fig. 2:
solid triangles). Moreover, the biochemical measurements
presented here were in agreement with the linear relation
proposed before when we measured the concentration of brain
Glc by 13C NMR methods in living rats (Choi et al., 2001)
(Fig. 2). No significant difference between the slopes of the
previous and present regression line was found. In both cases, at
plasma Glc levels lower than 2 mmol/l, the brain Glc
concentration approached 0 (Fig. 2, see also Fig. 4). Taken
together, these results show that the distribution of brain Glc
presented no substantial differences between isoflurane and a-
chloralose anesthetized rats.
We also studied whether total brain glycogen content can be
influenced by Glc and insulin. To assess the effects of Glc and
insulin separately, as well as administered together, rats from
group F (maintained for 5 h under a-chloralose anesthesia after
preparation) were used as control (see Table 1). As previously
observed (Choi et al., 2003), endogenous insulin secretion was
suppressed by somatostatin infusion as suggested from the
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Fig. 4. Insulin-induced hypoglycemia (<2 mmol/l plasma Glc) promoted
gradual glycogenolysis. First group (K) was measured after 30 min of hypo-
glycemia and second group (L) after 120 min. Control group (F) is shown as
mean  2 S.D. (95% confidence interval) in the shaded top band. Whereas,
plasma Glc represents the averaged values measured during 30 min (K) and
120 min (L) of hypoglycemia, brain Glc and glycogen are post-mortem
measurements. Errors bars indicate S.E.M. Abbreviation: Glc, glucose.
Fig. 3. Significant synergistic effect of brain glucose and insulin on brain
glycogen content. The groups of rats presented here were infused for 4 h either
in the presence of insulin (6 U/kg/h) or somatostatin (0.75 mg/kg/min) and their
glycemiawas kept close to 5 mM (groupG), 10 mM (groups H and I) and 20 mM
(group J). In the control group (F), there was no infusion of Glc (average plasma
Glc S.E.M.: 7.3  0.3 mM), and no exogenous administration of insulin or
somatostatin. Error bars indicate S.E.M. The slopes of regression lines are similar
and the intercepts are significantly different. Abbreviation: Glc, glucose.greatly reduced glucose infusion rate required to maintain
constant plasma glucose concentration (groups I and J). The
infusion of Glc, either alone (i.e. infused with somatostatin,
Fig. 3: compare group I and J) or administered together with
insulin (Fig. 3: compare group G and H), had a significant effect
on brain glycogen concentration (P = 0.02). This analysis was
achieved by including the correlation between brain glycogen
and brain glucose (PearsonR = 0.42,P = 0.03) in a general linear
modelwith brainGlc as covariable. The results showa significant
effect of brain Glc on brain glycogen and no significant
differencewas found between the slopes of the regression lines in
the two groups. Moreover, by eliminating the influence of brain
Glc concentration, our results also show a significant effect
(P = 0.03) of insulin on brain glycogen concentration. This
difference between the two experimental groups (with orwithout
somatostatin administration) with respect to the insulin con-
centration is explained by the significant (P = 0.03) difference
of the intercepts of the corresponding regression lines. Taken
together, these results show that there was a significant
synergistic effect of Glc and insulin in increasing brain glycogen
concentrations when administered together for 4 h.
The comparison between the measurements obtained here
using biochemical methods with previous 13C NMR measure-
ments of total brain glycogen was assessed. Considering the
rats that were infused for 4 h with 6 I.U./kg/h together with Glc
to maintain plasma Glc level close to 10 mmol/l (Table 1 and
Fig. 3: group H), there was an excellent agreement between
biochemical and previous 13C NMR measurements (average
brain glycogen concentration  S.E.M.: biochemical measure-
ment: 6.2  0.3 mmol/g and 13C NMR measurement:
5.8  0.2 mmol/g) (Choi et al., 2003). However, for the group
of rats that were infused with somatostatin together with Glc to
maintain plasma Glc level close to 10 mmol/l (Table 1 and
Fig. 3: group I), brain glycogen concentration obtained
previously by 13C NMR was significantly lower than the value
obtained here using biochemical methods (average brainglycogen concentration  S.E.M.: biochemical measurement:
5.3 0.3 mmol/g and 13C NMRmeasurement: 2.1 0.2 mmol/
g) (Choi et al., 2003).
Finally, the effect of hypoglycemia on brain glycogen
metabolism was assessed in the last groups of rats (Table 1:
groups K and L). At plasma Glc levels lower than 2 mmol/l
(mean  S.E.M.: 1.7 0.0 mmol/l), the brainGlc concentration
was 0.1 0.1 mmol/g (Fig. 4, see also Fig. 2). Although the
decrease of brain glycogen after only 30 min of hypoglycemia
was already significant (P < 0.05, Fig. 4: compare group K with
control group F), after 1.5 more hour of hypoglycemia, brain
glycogen concentration was significantly lower (P < 0.01,
Fig. 4: compare group L with K), but not yet completely
depleted. Brain glycogen concentration decreased from
3.1 0.4 mmol/g (group K) to 0.9 0.6 mmol/g (group L)
during 1.5 h, thus allowing to evaluate a glycogenolysis rate of
1.5 mmol/g/h. These results show that insulin-induced
moderate hypoglycemia promoted gradual glycogenolysis even
though brain Glc was similar in both hypoglycemic groups.
4. Discussion
Although 13C NMR is the only method to measure brain
glycogen non invasively, measurements of brain glycogen by
13C NMR are affected by in vivo turnover rates (Choi and
Gruetter, 2003; Choi et al., 2003; Choi et al., 1999; Oz et al.,
2003). Quantitative determination of glycogen content using
biochemical methods is challenging due to rapid post-mortem
degradation of brain glycogen and involves the study of a
higher number of animals (Cruz and Dienel, 2002; Kong et al.,
2002). Here, to minimize post-mortem degradation of this
labile compound, rats were sacrificed using a focused
microwave fixation device. In addition, tissue lactate concen-
tration was measured to ensure that post-mortem metabolism
had a negligible impact on the interpretation of the data. Overall
total brain glycogen concentrations obtained in the present
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NMR (Choi and Gruetter, 2003; Choi et al., 2001; Choi et al.,
2003) suggesting that 13C NMR allows for a correct
interpretation of glycogen concentration changes even in the
presence of label turnover.
When investigating the effects of anesthesia on brain
glycogen we noted a small increase in brain glycogen
concentration after 1 h 45 min under isoflurane anesthesia
compared to the rats that were only induced with isoflurane.
However, continuing under a-chloralose anesthesia for 5–8 h
resulted in minimal change in brain glycogen concentration
(Fig. 1). Clearly, a 2% isoflurane or light a-chloralose
anesthesia at 26.7 mg/kg/h I.V. does not result in the same
kinds of massive glycogen synthesis reported for pentobarbital
anesthesia (Choi et al., 2002; Nelson et al., 1968). During deep
pentobarbital anesthesia, it has been shown that the increase in
brain glycogen appeared to be related to the great diminution of
neuronal activity (Phelps, 1972). Likewise, anesthetics only
increase glycogen when applied in vivo, and not in astrocyte
cultures (Swanson et al., 1989). In the present study, the
anesthetics used allowed to maintain a light anesthesia state
(Ueki et al., 1992) and therefore produced a very small increase
in glycogen content.
The similarity of brain glycogen concentrations under
isoflurane and a-chloralose suggested a similar reduction in
brain energy metabolism for these two anesthetics. To confirm
this, we measured the effects of anesthesia on brain Glc which
has been shown to be sensitive to the levels of anesthesia (Choi
et al., 2002). The absence of a significant difference in the
distribution of brain Glc concentration as a function of plasma
Glc in the isoflurane compared to a-chloralose anesthetized rats
(Fig. 2) is additional evidence suggesting similar rates of brain
energy metabolism. This is unlike previously reported in deep
pentobarbital anesthesia where much higher brain Glc and
glycogen levels were observed (Choi et al., 2002). It further
suggests the notion of important control of glycogen content by
astrocytic glucose content. The observed linear relationship
between plasma and brain glucose is a consequence of using the
reversible Michaelis–Menten model of glucose transport to
describe glucose content (Choi et al., 2001; Choi et al., 2002;
Gruetter et al., 1998) and it is in excellent agreement with
previous 13C NMR methods in rats under a-chloralose
anesthesia (Choi et al., 2001).
The hypothesis that brain Glc might exert a control over
glycogen levels was further supported by increased brain Glc
resulting in increased brain glycogen concentration (Fig. 3).
Reciprocally, fasting did not affect Glc levels and therefore did
not substantially affect brain glycogen (Fig. 1), consistent with
brain Glc not being rate-limiting for metabolism in fasting. As
increased levels of Glc would raise insulin secretion, we also
tested the effects of insulin on brain glycogen. We showed that
insulin had an impact similar to Glc on increasing brain
glycogen concentration (Fig. 3). Moreover, there was a
significant synergistic effect of Glc and insulin in increasing
brain glycogen concentrations when administered together for
4 h. Endogenous insulin secretion was suppressed by soma-
tostatin infusion, therefore it is in principle possible thatsomatostatin triggers many actions in the brain. However, to our
knowledge, no direct effect of somatostatin per se on glycogen
metabolism has been reported in any organs. There might
potentially be indirect effects of somatostatin on brain glycogen
concentration through e.g. vasoactive intestinal peptide (VIP)
secretion inhibition (Allaman et al., 2000; Sorg andMagistretti,
1992), although it is more likely that the most important effects
of somatostatin resulting in a reduction of glycogen concentra-
tion are reflecting insulin secretion inhibition. It has already
been suggested that the concentration of glycogen may reflect
the combined effect of elevated plasma glucose and insulin to
promote net glycogen synthesis in the brain (Choi and Gruetter,
2003; Daniel et al., 1977; Nelson et al., 1968; Strang and
Bachelard, 1971). Here, we showed in rats under physiologic
plasma Glc concentrations that brain glycogen might be
regulated by Glc-dependent (Fig. 3, compare groups F, G and
H, or compare groups I and J) and Glc-independent (Fig. 3,
compare groups H and I), as well as insulin-dependent (Fig. 3,
compare groups H and I) and insulin-independent mechanisms
(Fig. 3, compare groups I and J). These findings are in excellent
agreement with previous 13C NMR measurements (Choi et al.,
2003). The experiments with somatostatin that resulted in lower
13C incorporation can be explained by an effect of low
concentration of insulin on the basal glycogen turnover rates.
The effect of Glc on brain glycogen was further studied in
acute moderate hypoglycemia (Fig. 4). When plasma Glc levels
were below 2 mM, the brain Glc concentration was close to 0,
consistent with Glc transport becoming rate limiting for whole
brain metabolism during hypoglycemia. This moderate
hypoglycemia promoted a gradual glycogenolysis at a rate
of 1.5 mmol/g/h. This value is in agreement with the
glycogenolytic flux of 0.038  0.005 mmol/g/min previously
estimated by 13C NMR spectroscopy (Choi et al., 2003). The
persistence of glycogen during hypoglycemia can be explained
by a partial Glc supply deficit (Gruetter, 2003). Thus, the brain
can store more than a few minutes’ supply of Glc equivalent as
glycogen, and brain glycogen is likely to play a significant role
during hypoglycemia.
Altogether, these results suggest that total brain glycogen
serves as a viable glucose reservoir during extended periods of
moderate hypoglycemia. Glycogen may be neuroprotective due
to increased glycogen breakdown to Glc-6-phospate during
hypoglycemia (Swanson and Choi, 1993). One possible
neuroprotective mechanism of glycogen is to provide ATP to
allow continuous uptake of excitotoxic glutamate from the
synaptic cleft (Gruetter, 2003) and to provide lactate as fuel for
neurons (Magistretti and Pellerin, 1996). Such neuroprotection
might interfere with proper recognition of hypoglycemia by
interfering with glucose-sensing neurons. It has been proposed
that brain glucose is the signal that triggers defense
mechanisms (for example, cerebral blood flow increase and
glycogen utilization) aimed at improving glucose equivalent
delivery to the brain during hypoglycemia (Choi et al., 2001). It
is also well known that type-1 diabetics who experience a single
hypoglycemic episode are more susceptible to succeeding
periods of hypoglycemia. The mechanism is unknown but in
addition to the sympathetic nervous system, Glc (Criego et al.,
F.D. Morgenthaler et al. / Neurochemistry International 48 (2006) 616–6226222005) and glycogen (Choi et al., 2003) may also be involved.
Therefore, glycogen might be implicated in the mechanism of
hypoglycemia unawareness syndrome observed clinically in
patients with type-1 diabetes, and may play a much more
important neuroprotective role in many disorders, such as sleep
deprivation, than previously assumed.
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